Trifecta Capital Advisors
VRTX icon

Trifecta Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Trifecta Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$9.03M Buy
17,267
+522
+3% +$267K 1.12% 28
2026
Q2 		$8.32M Sell
16,745
-12
-0.1% -$5.32K 1.07% 29
2026
Q1 		$7.48M Buy
16,757
+260
+2% +$121K 1.16% 29
2025
Q4 		$7.48M Buy
16,497
+664
+4% +$286K 1.11% 28
2025
Q3 		$6.2M Buy
15,833
+493
+3% +$206K 0.94% 36
2025
Q2 		$6.83M Buy
15,340
+802
+6% +$370K 1.14% 34
2025
Q1 		$7.05M Buy
14,538
+573
+4% +$267K 1.48% 20
2024
Q4 		$5.62M Buy
13,965
+430
+3% +$199K 1.11% 29
2024
Q3 		$6.29M Buy
13,535
+219
+2% +$105K 1.32% 22
2024
Q2 		$6.24M Buy
13,316
+955
+8% +$415K 1.38% 17
2024
Q1 		$5.17M Buy
12,361
+526
+4% +$222K 1.26% 23
2023
Q4 		$4.82M Buy
11,835
+350
+3% +$129K 1.33% 22
2023
Q3 		$3.99M Buy
11,485
+685
+6% +$240K 1.28% 22
2023
Q2 		$3.8M Buy
10,800
+990
+10% +$334K 1.22% 22
2023
Q1 		$3.09M Buy
9,810
+5,260
+116% +$1.58M 1.09% 26
2022
Q4 		$1.31M Buy
+4,550
New +$1.39M 0.52% 51

Other funds holding VRTX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Trifecta Capital Advisors's VRTX Position: Q3 2026 in Review

Trifecta Capital Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 3.1% in Q3 2026, buying an estimated $267K and bringing the position to 17,267 shares worth $9.03M. The position accounts for 1.12% of the portfolio, ranked #28.

Trifecta Capital Advisors first reported a position in VRTX in Q4 2022 and has held it in 16 quarters since. 1,069 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Trifecta Capital Advisors held 17,267 shares of Vertex Pharmaceuticals worth $9.03M as of Q3 2026.
  • Trifecta Capital Advisors bought 522 Vertex Pharmaceuticals shares in Q3 2026, an estimated $267K.
  • Vertex Pharmaceuticals made up 1.12% of Trifecta Capital Advisors's portfolio in Q3 2026, its #28 holding.
  • Trifecta Capital Advisors first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 16 quarters since.
  • 1,069 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Trifecta Capital Advisors's 13F filing for Q3 2026, filed 21 Oct 2026.